Do you need to worry about Mythos, Anthropic's computer-hacking AI? A powerful AI kept from public access because of its ability to hack computers with impunity is making headlines around the world. But what is Mythos, does it really represent a risk and might it even be used to improve cybersecurity? Anthropic's Project Glasswing aims to improve online security The past few weeks have brought apparently alarming news of Mythos, an AI that can identify cybersecurity flaws in a matter of moments, leaving operating systems and software vulnerable to hackers. The cybersecurity community is now beginning to get a better sense of how Mythos may change the face of cybersecurity - and not necessarily for the worse.

Disney and OpenAI have made a surprise deal - what happens next? Disney's famous Mickey Mouse character will soon be available for use in AI-generated videos The world's best-known AI company and the world's best-known entertainment firm have come to a surprise agreement to allow AI versions of some of the most iconic characters in film, TV and cartoons to be used in generative AI videos and images. Social media is dead - here's what comes next The Walt Disney Company has signed a deal with OpenAI that will allow the AI firm's Sora video generation tool and ChatGPT image creator to use more than 200 of Disney's most iconic characters. Meanwhile, Disney remains in dispute with another AI firm, Midjourney, over alleged infringement of their intellectual property (IP), claiming Midjourney aims to "blatantly incorporate and copy Disney's and Universal's famous characters" into their image generating tool. The characters now deemed fair game for OpenAI users include the likes of Mickey and Minnie Mouse, Simba and Mufasa from and Moana, as well as Marvel and Lucasfilm characters, including some of's most well-known names.

This work presents the development and evaluation of an NLP-enabled probabilistic classifier designed to estimate the probability of technical and regulatory success (pTRS) for clinical trials in the field of neuroscience. While pharmaceutical R&D is plagued by high attrition rates and enormous costs, particularly within neuroscience, where success rates are below 10%, timely identification of promising programs can streamline resource allocation and reduce financial risk. Leveraging data from the ClinicalTrials.gov database and success labels from the recently developed Clinical Trial Outcome dataset, the classifier extracts text-based clinical trial features using statistical NLP techniques. These features were integrated into several non-LLM frameworks (logistic regression, gradient boosting, and random forest) to generate calibrated probability scores. Model performance was assessed on a retrospective dataset of 101,145 completed clinical trials spanning 1976-2024, achieving an overall ROC-AUC of 0.64. An LLM-based predictive model was then built using BioBERT, a domain-specific language representation encoder. The BioBERT-based model achieved an overall ROC-AUC of 0.74 and a Brier Score of 0.185, indicating its predictions had, on average, 40% less squared error than would be observed using industry benchmarks. The BioBERT-based model also made trial outcome predictions that were superior to benchmark values 70% of the time overall. By integrating NLP-driven insights into drug development decision-making, this work aims to enhance strategic planning and optimize investment allocation in neuroscience programs.

Purpose: Thyroid cancer has been a common cancer. Papillary thyroid cancer and follicular thyroid cancer are the two most common types of thyroid cancer. Follicular thyroid cancer lacks distinctive ultrasound signs and is more difficult to diagnose preoperatively than the more prevalent papillary thyroid cancer, and the clinical studies associated with it are less well established. We aimed to analyze the clinical data of follicular thyroid cancer based on a novel data mining tool to identify some clinical indications that may help in preoperative diagnosis. Methods: We performed a retrospective analysis based on case data collected by the Department of General Surgery of Peking University Third Hospital between 2010 and 2023. Unlike traditional statistical methods, we improved the association rule mining, a classical data mining method, and proposed new analytical metrics reflecting the malignant association between clinical indications and cancer with the help of the idea of SHAP method in interpretable machine learning. Results: The dataset was preprocessed to contain 1673 cases (in terms of nodes rather than patients), of which 1414 were benign and 259 were malignant nodes. Our analysis pointed out that in addition to some common indicators (e.g., irregular or lobulated nodal margins, uneven thickness halo, hypoechogenicity), there were also some indicators with strong malignant associations, such as nodule-in-nodule pattern, trabecular pattern, and low TSH scores. In addition, our results suggest that the combination of Hashimoto's thyroiditis may also have a strong malignant association. Conclusion: In the preoperative diagnosis of nodules suspected of follicular thyroid cancer, multiple clinical indications should be considered for a more accurate diagnosis. The diverse malignant associations identified in our study may serve as a reference for clinicians in related fields.

In pharmaceutical R&D, predicting the efficacy of a pharmaceutical in treating a particular disease prior to clinical testing or any real-world use has been challenging. In this paper, we propose a flexible and modular machine learning-based approach for predicting the efficacy of an untested pharmaceutical for treating a disease. We train a machine learning model using sets of pharmaceutical-pathway weight impact scores and patient data, which can include patient characteristics and observed clinical outcomes. The resulting model then analyses weighted impact scores of an untested pharmaceutical across human biological molecule-protein pathways to generate a predicted efficacy value. We demonstrate how the method works on a real-world dataset with patient treatments and outcomes, with two different weight impact score algorithms We include methods for evaluating the generalisation performance on unseen treatments, and to characterise conditions under which the approach can be expected to be most predictive. We discuss specific ways in which our approach can be iterated on, making it an initial framework to support future work on predicting the effect of untested drugs, leveraging RWD clinical data and drug embeddings.

In this paper, we describe and benchmark a competitor-discovery component used within an agentic AI system for fast drug asset due diligence. A competitor-discovery AI agent, given an indication, retrieves all drugs comprising the competitive landscape of that indication and extracts canonical attributes for these drugs. The competitor definition is investor-specific, and data is paywalled/licensed, fragmented across registries, ontology-mismatched by indication, alias-heavy for drug names, multimodal, and rapidly changing. Although considered the best tool for this problem, the current LLM-based AI systems aren't capable of reliably retrieving all competing drug names, and there is no accepted public benchmark for this task. To address the lack of evaluation, we use LLM-based agents to transform five years of multi-modal, unstructured diligence memos from a private biotech VC fund into a structured evaluation corpus mapping indications to competitor drugs with normalized attributes. We also introduce a competitor validating LLM-as-a-judge agent that filters out false positives from the list of predicted competitors to maximize precision and suppress hallucinations. On this benchmark, our competitor-discovery agent achieves 83% recall, exceeding OpenAI Deep Research (65%) and Perplexity Labs (60%). The system is deployed in production with enterprise users; in a case study with a biotech VC investment fund, analyst turnaround time dropped from 2.5 days to $\sim$3 hours ($\sim$20x) for the competitive analysis.

While large language models (LLMs) are rapidly advancing scientific research, they continue to struggle with core biological reasoning tasks essential for translational and biomedical discovery. To address this limitation, we created and curated eight comprehensive benchmark datasets comprising over 300,000 verifiable question-and-answer pairs, each targeting critical challenges in drug discovery including target druggability, modality suitability, and drug perturbation effects. Using this resource, we developed the OwkinZero models by post-training open-source LLMs through a Reinforcement Learning from Verifiable Rewards strategy. Our results demonstrate that specialized 8-32B OwkinZero models substantially outperform larger, state-of-the-art commercial LLMs on these biological benchmarks. Remarkably, we uncover evidence of a key aspect of generalization: specialist models trained on a single task consistently outperform their base models on previously unseen tasks. This generalization effect is further amplified in our comprehensive OwkinZero models, which were trained on a mixture of datasets and achieve even broader cross-task improvements. This study represents a significant step toward addressing the biological reasoning blind spot in current LLMs, demonstrating that targeted reinforcement learning on carefully curated data can unlock generalizable performance in specialized models, thereby accelerating AI-driven biological discovery.

The beauty of physics is that there is usually a conserved quantity in an always-changing system, known as the constant of motion.